• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vor Biopharma Inc. - Common Stock (NQ:VOR)

    22.48 -1.11 (-4.71%)
    Streaming Delayed Price Updated: 1:16 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 544,219
    Open 23.48
    Bid (Size) 22.45 (100)
    Ask (Size) 22.50 (700)
    Prev. Close 23.59
    Today's Range 21.75 - 23.51
    52wk Range 6.500 - 50.20
    Shares Outstanding 66,956,800
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire

    Performance

    YTD
    +93.1%
    +93.1%
    1 Month
    +24.7%
    +24.7%
    3 Month
    +36.5%
    +36.5%
    6 Month
    +61.8%
    +61.8%
    1 Year
    -43.5%
    -43.5%

    More News

    Read More
    News headline image
    Vor Bio Appoints David Zaccardelli to Board of Directors
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Via The Motley Fool
    News headline image
    Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    What's Behind The Jump In Vor Biopharma Stock? ↗
    Via Benzinga
    News headline image
    Vor Bio Announces $75 Million Private Placement with TCGX
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    Vor Bio Announces $150 Million Private Placement
    From Vor Biopharma
    Via GlobeNewswire
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Vor Biopharma Inc. - Common Stock publicly traded?
    Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
    What exchange does Vor Biopharma Inc. - Common Stock trade on?
    Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
    The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
    What is the current price of Vor Biopharma Inc. - Common Stock?
    The current price of Vor Biopharma Inc. - Common Stock is 22.48
    When was Vor Biopharma Inc. - Common Stock last traded?
    The last trade of Vor Biopharma Inc. - Common Stock was at 08/12/26 01:16 PM ET
    What is the market capitalization of Vor Biopharma Inc. - Common Stock?
    The market capitalization of Vor Biopharma Inc. - Common Stock is 1.51B
    How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
    Vor Biopharma Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.